SaferSkin™ Launched at SOT

SaferSkin™
- integrated skin sensitisation assessment

An estimated 15-20% of the general population suffers from allergic contact dermatitis, or skin sensitisation. In fact, skin sensitisation is considered the most prevalent form of immunotoxicity found in humans, responsible for over seven million outpatient visits annually.*

SaferSkin™ is an easy-to-use software application which helps you determine, with confidence, the skin sensitisation potency of a substance according to accepted OECD guidelines. Applying three different and well-accepted scientific approaches, SaferSkin™ assesses input data, assigns a sensitisation category and calculates the level of confidence in the prediction. In one step, SaferSkin™ can help you make the best decisions in line with regulatory guidelines and best industry practices. SaferSkin™ supports the principles of the 3Rs of animal testing (Reduction, Refinement, Replacement) for more humane research.

Openness and transparency is in our company’s DNA so the SaferSkin™ Basic version is free and available to the global community. SaferSkin™ Professional offers additional and more advanced features at an affordable rate. The Enterprise version offers you the opportunity to define features for SaferSkin™ that are customised to your specific needs.

SaferSkin™ is the first of a range of chemical safety applications we have in the pipeline.

 

Get in touch for a free trial, or visit https://saferworldbydesign.com/saferskin/

 


* Kimber I, Basketter DA, Gerberick GF, Dearman RJ (2002). "Allergic contact dermatitis". Int. Immunopharmacol. 2 (2–3): 201–11. doi:10.1016/S1567-5769(01)00173-4. PMID 11811925

About Edelweiss Connect

Edelweiss Connect has developed computer software that helps combine data from many different sources and formats into a useable form for evaluation and re-use. In addition, we have developed other software programs that can use the collected data and data from in vitro tests to predict the safety of chemical compounds in the human body.

Tags

Latest Tweets

Edelweiss Connect (6 hours ago)
RT @barryhardy: Tatyana Doktorova will discuss current trends and developments in Adverse Outcome Pathways as exemplified by case studies (…
Edelweiss Connect (2 weeks ago)
Melanie Fischer, winner of the 2019 3RCC’s 3Rs Award, will present the toxicity test developed to use cultured fish… https://t.co/sDQecx5W2Q
Edelweiss Connect (2 weeks ago)
@EawagResearch researcher Melanie Fischer, winner of the 2019 3RCC’s 3Rs Award, will present the toxicity test deve… https://t.co/KaWTm3ClhT
Edelweiss Connect (2 weeks ago)
Last week's #OpenTox webinar on Trust in cloud-based Safety Assessment #blockchain #cybersecurity #dataintegrity… https://t.co/fHq5zInaEq
Edelweiss Connect (3 weeks ago)
#SaferWorldbyDesign presents: Towards Creating an engine of scientific discovery (SBX Corporation) #AI… https://t.co/Kgdh3oxqee

Get in touch

  • Address: Edelweiss Connect GmbH
    Technology Park Basel
    Hochbergerstrasse 60C
    CH-4057 Basel / Basel-Stadt
    Switzerland

USA office

  • Address: Edelweiss Connect Inc
    Research Triangle Park NC
    800 Park Offices Dr
    Durham, NC 27709
    USA